Today, AstraZeneca announced the formation of collaborative agreement with leading partners in Russia aimed at addressing most prevalent health issues in the Russian population and creating conditions for the development of personalized medicine.
Russian Venture Company Biofund, a Russian-based investment firm, and Quintiles, the world’s leading biopharmaceutical services company, today announced a definitive agreement to support expansion of clinical development services within the Russian Federation, the world’s ninth most populous country.